Takeda Pharmaceutical annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
Takeda Pharmaceutical EBITDA Growth & History (TAK)
Takeda Pharmaceutical's calculated EBITDA was ¥1.10T for fiscal 2025.
View full Takeda Pharmaceutical company overviewTakeda Pharmaceutical annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-03-31 | ¥1.10T | ¥161.91B | +17.19% |
| 2024 | 2024-03-31 | ¥942.08B | −¥212.83B | −18.43% |
| 2023 | 2023-03-31 | ¥1.15T | ¥110.91B | +10.62% |
| 2022 | 2022-03-31 | ¥1.04T | −¥24.95B | −2.33% |
| 2021 | 2021-03-31 | ¥1.07T | ¥384.88B | +56.26% |
| 2020 | 2020-03-31 | ¥684.06B | ¥198.68B | +40.93% |
| 2019 | 2019-03-31 | ¥485.38B | ¥61.46B | +14.50% |
| 2018 | 2018-03-31 | ¥423.92B | ¥96.62B | +29.52% |
| 2017 | 2017-03-31 | ¥327.29B | — | — |
Takeda Pharmaceutical quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Takeda Pharmaceutical ebitda trends
Over the last five reported fiscal years, Takeda Pharmaceutical's ebitda increased from ¥684.06B to ¥1.10T, a change of ¥419.93B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Takeda Pharmaceutical filings at SEC.gov ↗